Plain-English translation of NCT03536793 on ClinicalTrials.gov ↗ · Source last updated ·
Pancreatic cancer is often found very late, when treatment options are limited. This study is looking for biological markers—measurable signals in blood and fluid samples—that could help doctors spot pancreatic cancer much earlier, when surgery is still possible. Researchers will analyze samples from people with pancreatic cysts, those diagnosed with pancreatic cancer, and people with other pancreatic conditions to discover which markers best predict cancer risk.
Most pancreatic cancer is diagnosed at an advanced stage when the outlook is poor. If doctors could detect it earlier—even before it fully develops—more patients could have surgery and better outcomes. Current tests for pancreatic cancer are invasive and uncomfortable. This research aims to find simpler blood and fluid markers that could catch cancer at its earliest stages.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will donate blood, urine, and sometimes fluid samples, usually on the same day as a procedure you're already having for your medical care. Samples will be sent to a research laboratory where scientists will analyze them for biological markers and genetic information. There are no follow-up visits required—participation involves a single sample collection as part of your routine medical care.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
United Kingdom